Search Medical Condition
Please enter condition
Please choose location from dropdown

Lakewood, Ohio Clinical Trials

A listing of Lakewood, Ohio clinical trials actively recruiting patient volunteers.

RESULTS

Found (280) clinical trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II III or IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine if women who are disease-free after successfully completing primary and potential consolidation/maintenance, therapy for stage II-IV ovarian, fallopian tube or primary peritoneal cancer and who are randomized to a healthy lifestyle intervention, will have significantly increased progression-free survival compared to similar women who are randomized ...

Phase

2.11 miles

Learn More »

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

PRIMARY OBJECTIVES: I. To assess whether pelvic radiation therapy with concurrent cisplatin is more promising with respect to progression-free survival than pelvic radiation therapy alone in the treatment of recurrent uterine carcinoma limited to the pelvis and vagina. SECONDARY OBJECTIVES: I. To capture the sites of recurrence subsequent to treatment ...

Phase

2.11 miles

Learn More »

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

PRIMARY OBJECTIVES: I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. SECONDARY OBJECTIVES: I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate ...

Phase

2.11 miles

Learn More »

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

PRIMARY OBJECTIVES: I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related ...

Phase

2.11 miles

Learn More »

PeriOperative ISchemic Evaluation-3 Trial

The POISE-3 study is a 10,000 patient, multicentre, international, non-inferiority randomized controlled trial of tranexamic acid (TXA) versus placebo and, using a partial factorial design, of a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The primary objective of the study is to determine; if TXA is superior to placebo for the occurrence ...

Phase

2.11 miles

Learn More »

Danger Signs in Heart Failure- Effects of Video Education

The most frequently cited danger signs of heart failure (HF) are new onset or worsening of fatigue, dyspnea and edema. In previous research, patients did not recognize worsening HF, due to 3 primary reasons: (1) danger signs were non-specific and misinterpreted as stress, an external force or another comorbidity, (2) ...

Phase N/A

2.11 miles

Learn More »

Testing The Addition of a New Anti-cancer Drug Venetoclax to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated Older Patients With Chronic Lymphocytic Leukemia

PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) between control treatment and experimental treatment strategies: ibrutinib/obinutuzumab (IO) with ibrutinib maintenance (IM) versus ibrutinib/venetoclax/obinutuzumab (IVO) regardless of IM or observation. SECONDARY OBJECTIVES: I. To compare bone marrow (BM) minimal residual disease (MRD)- complete response (CR) rates and depth of response ...

Phase

2.11 miles

Learn More »

Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response

PRIMARY OBJECTIVES: I. To determine the effect of maintenance obinutuzumab on duration of complete response (CR) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain CR to first-line treatment with high-dose methotrexate-based chemotherapy. SECONDARY OBJECTIVES: I. To evaluate overall survival after CR (overall survival [OS]-CR). II. ...

Phase

2.11 miles

Learn More »

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Angion Biomedica Corp. has developed a small molecule hepatocyte growth factor/scatter factor (HGF/SF) mimetic, termed ANG-3777, which exerts significant nephroprotective effects in several preclinical renal injury models. Angion intends to develop ANG-3777 as a therapy to prevent and/or treat acute kidney injury. ANG-3777 is a new molecular entity and the ...

Phase

2.11 miles

Learn More »

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients treated with durvalumab (MEDI4736) plus tremelimumab. SECONDARY OBJECTIVES: I. To estimate the duration of response (DoR) among patients who achieve a complete response (CR) ...

Phase

2.11 miles

Learn More »